Leukemia Clinical Trials in Los Angeles

Showing 641-654 of 654 trials

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

NCT00363974

The purpose of this study is to determine if the drug, called AEG35156, can be safely given to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy (ara-C and idarubicin) in patients with refractory or relapsed AML.

Leukemia, Myelomonocytic, Acute

Aegera Therapeutics54 participantsStarted Oct 2005

Los Angeles, California, United States • Los Angeles, California, United States • Chicago, Illinois, United States +4 more locations

COMPLETEDPHASE2< 1 mile

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

NCT00129844

The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.

AdenocarcinomaNon-Small-Cell Lung CarcinomaLung Neoplasms

Pharmacyclics LLC.108 participantsStarted Sep 2005

Fountain Valley, California, United States • Los Angeles, California, United States • Palm Springs, California, United States +13 more locations

COMPLETEDPHASE2< 1 mile

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Spectrum Pharmaceuticals, Inc114 participantsStarted Apr 2004

Berkeley, California, United States • Burbank, California, United States • Los Angeles, California, United States +4 more locations

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Leukemia Trials in Other Cities

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Amonafide in Combination With Cytarabine in Secondary AML

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Los Angeles